Advertisement


Francesca Battaglin, MD, on Colorectal Cancer: Using Genetic Variants to Predict Treatment Efficacy

2019 Gastrointestinal Cancers Symposium

Advertisement

Francesca Battaglin, MD, of the University of Southern California Norris Comprehensive Cancer Center, discusses phase III study data on genetic variants used to predict the efficacy of cetuximab in patients with metastatic colorectal cancer (Abstract 564).



Related Videos

Hepatobiliary Cancer
Immunotherapy

Ahmed Omar Kaseb, MD, on Liver Cancer: Results From an Immunotherapy Trial

Ahmed Omar Kaseb, MD, of The University of Texas MD Anderson Cancer Center, discusses phase II study findings on nivolumab alone vs nivolumab plus ipilimumab in patients with...

Colorectal Cancer

Pieter Tanis, MD, PhD, on Colon Cancer: Results From the COLOPEC Trial on Adjuvant HIPEC

Pieter Tanis, MD, PhD, of Amsterdam University Medical Centers, discusses study findings on adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with colon ...

Gastrointestinal Cancer

David H. Ilson, MD, PhD, on Gastric Cancer: Results From the TAGS Study on Third-Line Trifluridine/Tipiracil

David H. Ilson, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses findings on the efficacy and safety of third-line trifluridine/tipiracil in patients with metast...

Gastroesophageal Cancer
Immunotherapy

Takashi Kojima, MD, on Esophageal Cancer: Results From the KEYNOTE-181 Trial on Immunotherapy vs Chemotherapy

Takashi Kojima, MD, of the National Cancer Center Hospital East, discusses phase III study findings on pembrolizumab vs chemotherapy as second-line treatment for advanced eso...

Neuroendocrine Tumors
Immunotherapy

Jonathan R. Strosberg, MD, on Neuroendocrine Tumors: Results From the KEYNOTE-158 Trial on PD-1 Inhibition

Jonathan R. Strosberg, MD, of the Moffitt Cancer Center, discusses phase II study findings on pembrolizumab as a treatment for advanced neuroendocrine tumors (Abstract 190).<...

Advertisement

Advertisement



;
Advertisement